Nasal Drug Delivery

Nasal administration has been on the rise in recent years, largely due to a surge in respiratory products from the global pandemic plus an innovation push towards non-standard formats that bypass the first-pass metabolism. According to PharmaCircle, it is estimated that nasal products currently comprise approximately 20% of the preclinical prescription pipeline, versus only 7% of marketed products, demonstrating their growing popularity.

With the increasing interest in nasal drug delivery, there has also been a rise in products seeking to protect patients from respiratory infections. The primary way that respiratory viruses and bacteria enter the body is through the nasal passage. Therefore, one emerging method of protection is the development of nasal sprays that create a barrier on mucosa to prevent pathogen adherence and proliferation, which subsequently helps shield against infection.

Our Carbopol® and Noveon® polymers can add significant value in nasal applications, via:

• Shielding Against Infection - creating a barrier on mucosa that prevents pathogen adherence and proliferation
• Bioadhesion / Mucoadhesion – optimizing drug delivery by prolonging product contact with nasal tissue, improving patient compliance via reduced need for frequent drug administration, and protecting and lubricating the nasal mucosal surface
• Uniform Drug Distribution - imparting homogenous spray pattern of drug-containing formulations in the nasal cavity